LOT1:NUF01-NUF04-NUF06-NUF11-NUI02-NUI12 Nuclear Medicine - Radiopharmaceuticals

This tender concerns the supply of radiopharmaceuticals for Nuclear Medicine applications, specifically designated under LOT1, encompassing codes NUF01, NUF04, NUF06, NUF11, NUI02, and NUI12. The procurement focuses on essential materials required for diagnostic and therapeutic procedures within the field of nuclear medicine. Bidders are expected to provide high-quality radiopharmaceutical products that meet stringent regulatory and safety standards. The scope of work likely involves the regular delivery of these specialized substances, ensuring continuity of service for healthcare facilities. Key requirements may include adherence to Good Manufacturing Practices (GMP), specific packaging and handling protocols for radioactive materials, and timely delivery schedules. The tender aims to secure a reliable supply chain for these critical medical isotopes, supporting advanced diagnostic imaging and targeted therapies. Further details regarding the specific quantities, technical specifications, delivery locations, and evaluation criteria will be provided in the full tender documentation. Interested parties should review the complete tender package to understand the full scope and eligibility requirements for this procurement opportunity in the nuclear medicine sector.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Spain, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 4.0 million.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.